Show simple item record

FieldValueLanguage
dc.contributor.authorLeung, Sharon S.Y.
dc.contributor.authorParumasivam, Thaigarajan
dc.contributor.authorNguyen, An
dc.contributor.authorGengenbach, Thomas
dc.contributor.authorCarter, Elizabeth
dc.contributor.authorCarrigy, Nicholas
dc.contributor.authorWang, Hui
dc.contributor.authorVehring, Reinhard
dc.contributor.authorFinlay, Warren
dc.contributor.authorMorales, Sandra
dc.contributor.authorBritton, Warwick
dc.contributor.authorKutter, Elizabeth
dc.contributor.authorChan, Hak-Kim
dc.date.accessioned2018-04-04
dc.date.available2018-04-04
dc.date.issued2018-03-02
dc.identifier.urihttps://doi.org/10.1016/j.ejpb.2018.02.033
dc.identifier.urihttp://hdl.handle.net/2123/18059
dc.description.abstractThis study aimed to assess the robustness of using a spray drying approach and formulation design in producing inhalable phage powders. Two types of Pseudomonas phages, PEV2 (Podovirus) and PEV40 (Myovirus) in two formulations containing different amounts of trehalose (70% and 60%) and leucine (30% and 40%) were studied. Most of the surface of the produced powders was found to be covered in crystalline leucine. The powders were stored at 4 °C and 20 °C under vacuum. The phage stability and in vitro aerosol performance of the phage powders were examined on the day of production and after 1, 3 and 12 months of storage. A minor titer loss during production was observed for both phages (0.2–0.8 log10 pfu/ml). The storage stability of the produced phage powders was found to be phage and formulation dependent. No further reduction in titer occurred for PEV2 powders stored at 4 °C across the study. The formulation containing 30% leucine maintained the viability of PEV2 at 20 °C, while the formulation containing 40% leucine gradually lost titer over time with a storage reduction of ∼0.9 log10 pfu/ml measured after 12 months. In comparison, the PEV40 phage powders generally had a ∼ 0.5 log10 pfu/ml loss upon storage regardless of temperature. When aerosolized, the total in vitro lung doses of PEV2 were of the order of 107 pfu, except the formulation containing 40% leucine stored at 20 °C which had a lower lung dose. The PEV40 powders also had lung doses of 106–107 pfu. The results demonstrate that spray dried Myoviridae and Podoviridae phage in a simple formulation of leucine and trehalose can be successfully stored for one year at 4 °C and 20 °C with vacuum packaging.en_AU
dc.description.sponsorshipThe University of Sydney; Australian Research Council; National Institute of Allergy and Infectious Diseases of the National Institutes of Health; National Health and Medical Research Council Centre of Research Excellence in Tuberculosis Controlen_AU
dc.language.isoen_USen_AU
dc.publisherElsevieren_AU
dc.relationDP150103953en_AU
dc.subjectPhageen_AU
dc.subjectPEV2en_AU
dc.subjectPEV40en_AU
dc.subjectPulmonary infectionsen_AU
dc.subjectPhage dry powderen_AU
dc.subjectAntibiotic resistanceen_AU
dc.titleEffect of storage temperature on the stability of spray dried bacteriophage powdersen_AU
dc.typeArticleen_AU
dc.subject.asrcFoR::111504 - Pharmaceutical Sciencesen_AU
dc.subject.asrcFoR::090406 - Powder and Particle Technologyen_AU
dc.subject.asrcFoR::110203 - Respiratory Diseasesen_AU
dc.subject.asrcFoR::110309 - Infectious Diseasesen_AU
dc.identifier.doihttps://doi.org/10.1016/j.ejpb.2018.02.033
dc.type.pubtypePre-printen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.